SPOTLIGHT: Synta, GSK gain orphan drug designation

The FDA has granted its orphan drug designation to elesclomol, an investigational drug that treats metastatic melanoma. The drug is being advanced by a collaboration between Synta and GlaxoSmithKline. Release

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.